Pfizer Sets Its Sights High for 2025

Pfizer Inc. unveiled its fiscal 2025 guidance on Tuesday, projecting annual revenue to range between $61 billion and $64 billion. This forecast includes steady sales of its COVID-19 products compared to 2024 levels.

The pharmaceutical giant anticipates its adjusted diluted earnings per share (EPS) to fall within $2.80 and $3.00, reflecting an operational growth of 10% to 18% year-over-year from the midpoint of its 2024 baseline guidance.

"We've achieved our goal of $4 billion in net operating expense savings through 2024 from our cost realignment program, with an additional $500 million expected in 2025," remarked CEO Dr. Albert Bourla.

Pfizer's stock experienced a 2.50% surge during premarket hours, trading at $25.88 per share.